These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 4271320)

  • 1. Immunotherapy for acute myelogenous leukaemia.
    Powles RL; Crowther D; Bateman CJ; Beard ME; McElwain TJ; Russell J; Lister TA; Whitehouse JM; Wrigley PF; Pike M; Alexander P; Fairley GH
    Br J Cancer; 1973 Nov; 28(5):365-76. PubMed ID: 4271320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for acute myelogenous leukemia.
    Powles RL; Lister TA; Crowther D; McElwain T; Alexander P; Fairley GH
    Bibl Haematol; 1975; (40):737-49. PubMed ID: 1057948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of adult acute myelogenous leukaemia.
    Crowther D; Powles RL; Bateman CJ; Beard ME; Gauci CL; Wrigley PF; Malpas JS; Fairley GH; Scott RB
    Br Med J; 1973 Jan; 1(5846):131-7. PubMed ID: 4513355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
    Harris R; Zuhrie SR; Freeman CB; Taylor GM; MacIver JE; Geary CG; Delamore IW; Hull PJ; Tooth JA
    Br J Cancer; 1978 Feb; 37(2):282-8. PubMed ID: 272913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoimmunotherapy for maintenance in acute myeloblastic leukemia.
    Whiteside MG; Cauchi MN; Paton C; Stone J
    Cancer; 1976 Oct; 38(4):1581-6. PubMed ID: 1068741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.
    Powles RL; Russell J; Lister TA; Oliver T; Whitehouse JM; Malpas J; Chapuis B; Crowther D; Alexander P
    Br J Cancer; 1977 Mar; 35(3):265-72. PubMed ID: 322689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of immunotherapy on survival of patients with acute myelogenous leukaemia after relapse.
    Powles R; Toy JL
    Haematologia (Budap); 1976; 10(1):5-9. PubMed ID: 1070466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance of remission in acute myelogenous leukaemia by a mixture of B.C.G. and irradiated leukaemia cells.
    Powles RL; Russell JA; Selby PJ; Prentice HG; Jones DR; McElwain TJ; Alexander P
    Lancet; 1977 Nov; 2(8048):1107-10. PubMed ID: 73013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
    Zuhrie SR; Harris R; Freeman CB; MacIver JE; Geary CG; Delamore IW; Tooth JA
    Br J Cancer; 1980 Mar; 41(3):372-7. PubMed ID: 6992827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nature of remission in acute myeloblastic leukaemia.
    Powles RL; Selby PJ; Palu G; Morgenstern G; McElwain TJ; Clink HM; Alexander P
    Lancet; 1979 Sep; 2(8144):674-6. PubMed ID: 90762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of acute myelogenous leukemia in man.
    Powles R
    Natl Cancer Inst Monogr; 1973 Dec; 39():243-7. PubMed ID: 4595324
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy with chemotherapy in the maintenance of remission in acute myeloblastic leukaemia.
    Whiteside MG; Cauchi MV; Paton CM
    Med J Aust; 1976 Jul; 2(1):10-3. PubMed ID: 1068338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and immunotherapy for acute myelogenous leukemia.
    Lister TA; Whitehouse JM; Oliver RT; Bell R; Johnson SA; Wrigley PF; Ford JM; Cullen MH; Gregory W; Paxton AM; Malpas JS
    Cancer; 1980 Nov; 46(10):2142-8. PubMed ID: 6932992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active specific immunotherapy for acute myelogenous leukaemia.
    Powles R
    Johns Hopkins Med J Suppl; 1974; 3():333-40. PubMed ID: 4609353
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy of acute myeloid leukaemia. Medical Research Council.
    Br J Cancer; 1978 Jan; 37(1):1-14. PubMed ID: 339940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active immunotherapy for the treatment of acute myelogenous leukaemia: report of two controlled trials.
    Whittaker JA; Bailey-Wood R; Hutchins S
    Br J Haematol; 1980 Jul; 45(3):389-400. PubMed ID: 7000149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for remission maintenance in acute myeloblastic leukemia.
    Baker MA; Taub RN; Carter WH
    Cancer Immunol Immunother; 1982; 13(2):85-8. PubMed ID: 6760961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and immunotherapy interspersion: clinical studies in acute myeloblastic leukaemia.
    Whittaker JA
    Recent Results Cancer Res; 1977; (62):90-4. PubMed ID: 341252
    [No Abstract]   [Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
    N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Immunotherapy for acute myeloid leukaemia.
    Lancet; 1974 May; 1(7862):846-7. PubMed ID: 4132795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.